These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 35146532)

  • 21. Secukinumab in the treatment of psoriatic arthritis or ankylosing spondyloarthritis with multiple sclerosis: a case series with literature review.
    Eksin MA; Erden A; Güven SC; Armagan B; Ozdemir B; Karakas O; Omma A; Kucuksahin O
    Immunotherapy; 2022 Apr; 14(6):401-408. PubMed ID: 35152720
    [No Abstract]   [Full Text] [Related]  

  • 22. Inflammatory bowel disease new-onset during secukinumab therapy: real-world data from a tertiary center.
    Ojeda Gómez A; Madero Velázquez L; Buendía Sanchez L; Pascual Sánchez I; Pérez Rabasco E; García Monsalve A; González Ferrández JA; García Sepulcre MF
    Rev Esp Enferm Dig; 2021 Dec; 113(12):858-859. PubMed ID: 34696593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Husni ME; Deodhar A; Schwartzman S; Chakravarty SD; Hsia EC; Leu JH; Zhou Y; Lo KH; Kavanaugh A
    Arthritis Res Ther; 2022 Mar; 24(1):73. PubMed ID: 35313978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Secukinumab: A Review in Psoriatic Arthritis.
    Shirley M; Scott LJ
    Drugs; 2016 Jul; 76(11):1135-45. PubMed ID: 27299434
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Psoriasis vulgaris patient with psoriatic arthritis managed with interleukin-17A inhibitor: Balancing benefits and adverse effects.
    Utama WS; Lestari W; Hajar S; Sylvawani M; Ismida FD; Akele RY
    Narra J; 2024 Apr; 4(1):e207. PubMed ID: 38798877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient clusters identified by machine learning from a pooled analysis of the clinical development programme of secukinumab in psoriatic arthritis, ankylosing spondylitis and psoriatic arthritis with axial manifestations.
    Baraliakos X; Pournara E; Coates LC; Mease PJ; Jahandideh SS; Gladman DD
    Clin Exp Rheumatol; 2024 Mar; 42(3):696-701. PubMed ID: 38019168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials.
    Curtis JR; Mariette X; Gaujoux-Viala C; Blauvelt A; Kvien TK; Sandborn WJ; Winthrop K; de Longueville M; Huybrechts I; Bykerk VP
    RMD Open; 2019; 5(1):e000942. PubMed ID: 31245056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.
    Baeten D; Baraliakos X; Braun J; Sieper J; Emery P; van der Heijde D; McInnes I; van Laar JM; Landewé R; Wordsworth P; Wollenhaupt J; Kellner H; Paramarta J; Wei J; Brachat A; Bek S; Laurent D; Li Y; Wang YA; Bertolino AP; Gsteiger S; Wright AM; Hueber W
    Lancet; 2013 Nov; 382(9906):1705-13. PubMed ID: 24035250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secukinumab (AIN457) in the treatment of ankylosing spondylitis.
    Braun J; Baraliakos X; Kiltz U
    Expert Opin Biol Ther; 2016; 16(5):711-22. PubMed ID: 26982813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis.
    Deodhar A; Gladman DD; McInnes IB; Spindeldreher S; Martin R; Pricop L; Porter B; Safi J; Shete A; Bruin G
    J Rheumatol; 2020 Apr; 47(4):539-547. PubMed ID: 31203228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA study.
    Augustin M; Sator PG; von Kiedrowski R; Conrad C; Rigopoulos D; Romanelli M; Ghislain PD; Torres T; Ioannides D; Aassi M; Schulz B; Jagiello P;
    J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):1796-1804. PubMed ID: 35696305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Secukinumab for rheumatology: development and its potential place in therapy.
    Koenders MI; van den Berg WB
    Drug Des Devel Ther; 2016; 10():2069-80. PubMed ID: 27445458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative.
    Colombo GL; Di Matteo S; Martinotti C; Jugl SM; Gunda P; Naclerio M; Bruno GM
    Clinicoecon Outcomes Res; 2018; 10():477-491. PubMed ID: 30214261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and effectiveness of intravenous CT-P13 in inflammatory arthritis: post-marketing surveillance study in Thailand.
    Mahakkanukrauh A; Chaiamnuay S; Koolvisoot A; Kitamnuayphong T; Manavathongchai S; Osiri M; Louthrenoo W; Uea-Areewongsa P; Ahn K; Jung N; Kim M; Lee S; Kim H; Kim S
    Immunotherapy; 2023 Oct; 15(14):1143-1155. PubMed ID: 37589164
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of secukinumab for the treatment of active ankylosing spondylitis.
    Loricera J; Galíndez-Aguirregoikoa E; Blanco R
    Expert Opin Drug Saf; 2021 Jun; 20(6):627-634. PubMed ID: 33470130
    [No Abstract]   [Full Text] [Related]  

  • 36. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
    Kay J; Fleischmann R; Keystone E; Hsia EC; Hsu B; Mack M; Goldstein N; Braun J; Kavanaugh A
    Ann Rheum Dis; 2015 Mar; 74(3):538-46. PubMed ID: 24344160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis.
    Reis J; Vender R; Torres T
    BioDrugs; 2019 Aug; 33(4):391-399. PubMed ID: 31172372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ixekizumab for the treatment of psoriasis: an update on new data since first approval.
    Blegvad C; Skov L; Zachariae C
    Expert Rev Clin Immunol; 2019 Feb; 15(2):111-121. PubMed ID: 30589394
    [No Abstract]   [Full Text] [Related]  

  • 39. One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study.
    Chimenti MS; Fonti GL; Conigliaro P; Sunzini F; Scrivo R; Navarini L; Triggianese P; Peluso G; Scolieri P; Caccavale R; Picchianti Diamanti A; De Martino E; Salemi S; Birra D; Altobelli A; Paroli M; Bruzzese V; Laganà B; Gremese E; Conti F; Afeltra A; Perricone R
    Expert Opin Biol Ther; 2020 Jul; 20(7):813-821. PubMed ID: 32401062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort.
    Molica Colella F; Zizzo G; Parrino V; Filosa MT; Cavaliere R; Fazio F; Molica Colella AB; Mazzone A
    Adv Rheumatol; 2023 Mar; 63(1):15. PubMed ID: 36973825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.